Since ICB therapy can reverse the immunosuppressive microenvironment, combining ICB with DC vaccines has been found to activate CD8+ T cells in vivo and can be synergized with PD-1 blockers to exert anti-tumour immunity [216]. Here, CD8A is linked to neoplasm.